Human Genome Sciences, Inc. (HGSI), Monday said that it has commenced an underwritten public offering of up to 12.50 million shares of its common stock. The Company intends to grant the underwriters a 30-day option to purchase up to an additional 1.87 million shares of the company's common stock.
Net proceeds from this offering is expected to use for general corporate purposes, including acquisition of additional manufacturing capacity and development of new indications for BENLYSTA, as well as potential sales and marketing activities, clinical trial, research and development, general and administrative and manufacturing expenses and the potential retirement of debt. The company will also use a portion of the proceeds for strategic investments.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.